001     859196
005     20210130000209.0
024 7 _ |a 10.1093/neuonc/noz003
|2 doi
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a altmetric:53509404
|2 altmetric
024 7 _ |a pmid:30615138
|2 pmid
024 7 _ |a WOS:000473768600005
|2 WOS
037 _ _ |a FZJ-2019-00086
082 _ _ |a 610
100 1 _ |a Galldiks, Norbert
|0 P:(DE-Juel1)143792
|b 0
|e Corresponding author
|u fzj
245 _ _ |a PET Imaging in Patients with Brain Metastasis - Report of the RANO/PET Group
260 _ _ |a Oxford
|c 2019
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1557995766_28761
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Brain metastases (BM) from extracranial cancer are associated with significant morbidity and mortality. Effective local treatment options are stereotactic radiotherapy, including radiosurgery or fractionated external beam radiotherapy, and surgical resection. The use of systemic treatment for intracranial disease control also is improving. BM diagnosis, treatment planning, and follow-up is most often based on contrast-enhanced magnetic resonance imaging (MRI). However, anatomic imaging modalities including standard MRI have limitations in accurately characterizing posttherapeutic reactive changes and treatment response. Molecular imaging techniques such as positron emission tomography (PET) characterize specific metabolic and cellular features of metastases, potentially providing clinically relevant information supplementing anatomic MRI. Here, the Response Assessment in Neuro-Oncology working group provides recommendations for the use of PET imaging in the clinical management of patients with BM based on evidence from studies validated by histology and/or clinical outcome.
536 _ _ |a 572 - (Dys-)function and Plasticity (POF3-572)
|0 G:(DE-HGF)POF3-572
|c POF3-572
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef
700 1 _ |a Langen, Karl-Josef
|0 P:(DE-Juel1)131777
|b 1
|u fzj
700 1 _ |a Albert, Nathalie L
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Chamberlain, Marc
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Soffietti, Riccardo
|0 P:(DE-HGF)0
|b 4
700 1 _ |a Kim, Michelle M
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Law, Ian
|0 P:(DE-HGF)0
|b 6
700 1 _ |a Le Rhun, Emilie
|0 P:(DE-HGF)0
|b 7
700 1 _ |a Chang, Susan
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Schwarting, Julian
|0 P:(DE-HGF)0
|b 9
700 1 _ |a Combs, Stephanie E
|0 P:(DE-HGF)0
|b 10
700 1 _ |a Preusser, Matthias
|0 P:(DE-HGF)0
|b 11
700 1 _ |a Forsyth, Peter
|0 P:(DE-HGF)0
|b 12
700 1 _ |a Pope, Whitney
|0 P:(DE-HGF)0
|b 13
700 1 _ |a Weller, Michael
|0 P:(DE-HGF)0
|b 14
700 1 _ |a Tonn, Jörg C
|0 P:(DE-HGF)0
|b 15
773 _ _ |a 10.1093/neuonc/noz003
|0 PERI:(DE-600)2094060-9
|n 5
|p 585-595
|t Neuro-Oncology
|v 21
|y 2019
|x 1523-5866
856 4 _ |u https://juser.fz-juelich.de/record/859196/files/noz003.pdf
|y Restricted
856 4 _ |u https://juser.fz-juelich.de/record/859196/files/noz003.pdf?subformat=pdfa
|x pdfa
|y Restricted
909 C O |o oai:juser.fz-juelich.de:859196
|p VDB
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 0
|6 P:(DE-Juel1)143792
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 1
|6 P:(DE-Juel1)131777
913 1 _ |a DE-HGF
|b Key Technologies
|l Decoding the Human Brain
|1 G:(DE-HGF)POF3-570
|0 G:(DE-HGF)POF3-572
|2 G:(DE-HGF)POF3-500
|v (Dys-)function and Plasticity
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2017
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NEURO-ONCOLOGY : 2017
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-3-20090406
|k INM-3
|l Kognitive Neurowissenschaften
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-Juel1)INM-3-20090406
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21